Biocon: To benefit from Mylan-Lupin partnership

This is second such arrangement when Biocon will receive economic benefits when Mylan commercializes a biosimilar, not developed by Biocon.

Jun 28, 2018 02:06 IST India Infoline News Service

Biocon Limited
Biocon has said that it will benefit from the Mylan/Lupin partnership on Enbrel biosimilar. Lupin, in the morning, announced that it has entered in a partnership pact with Mylan to commercialize Enbrel biosimilar.

Under the terms of the agreement, Lupin will receive an up-front payment of $15mn and potential commercial milestones together with an equal share in net profits of the product.

Biocon has said that it retains its economic interest in this arrangement vis-a-vis Mylan in accordance with its existing collaboration agreement and would benefit from the opportunity to accelerate commercialization of Enbrel. Biocon’s Enbrel biosimilar is at pre-clinical levels and far from the approval stage.

This is second such arrangement in which its partner Mylan has partnered with a differet pharma company to acclerate the biosimilar commercialization.

The first was Mylan entered with Fujifilm for Humira biosimilar in April 2018. Biocon will also receive economic benefit through this collaboration.

Related Story

Open Free Demat Account (Rs699)